8-K Announcements
6Material company update
Apr 2, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Nov 10, 2025·SEC
Celldex Therapeutics, Inc.(CLDX)Earnings, Financials & Key Ratios
CLDX•NASDAQ
$34.39
$2.29B mkt cap·Price updated May 6, 2026
AboutCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.Show more
- Revenue$2M-78.6%
- EBITDA-$284M-48.0%
- Net Income-$259M-63.9%
- EPS (Diluted)-3.90-59.2%
- Gross Margin100%+104.5%
- EBITDA Margin-18934.67%-592.7%
- Operating Margin-19160%-589.5%
- Net Margin-17253.33%-667.2%
- ROE-40.62%-51.3%
- ROIC-35.25%-34.8%
- Debt/Equity0.00-13.2%
CLDX Key Insights
Celldex Therapeutics, Inc. (CLDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Sales declining 27.4% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CLDX Price & Volume
Celldex Therapeutics, Inc. (CLDX) stock price & volume — 10-year historical chart
Loading chart...
CLDX Growth Metrics
Celldex Therapeutics, Inc. (CLDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-12.15%
5 Years-27.36%
3 Years-13.98%
TTM-78.63%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-63.94%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-59.18%
Return on Capital
10 Years-40.26%
5 Years-33.99%
3 Years-39.27%
Last Year-44.74%
CLDX Recent Earnings
Celldex Therapeutics, Inc. (CLDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (45%)
Q1 2026Latest
Feb 25, 2026EPS
$1.22
Est $1.00
-22.0%
Revenue
$100,000
Est $1M
-92.4%
Q4 2025
Nov 10, 2025EPS
$1.01
Est $0.88
-14.8%
Revenue
—
Est $2M
Q3 2025
Aug 7, 2025EPS
$0.85
Est $0.86
+1.2%
Revenue
$730,000
Est $1M
-38.3%
Q2 2025
May 8, 2025EPS
$0.81
Est $0.75
-8.0%
Revenue
$695,000
Est $1M
-38.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $1.22vs $1.00-22.0% | $100,000vs $1M-92.4% |
| Q4 2025 | Nov 10, 2025 | $1.01vs $0.88-14.8% | —vs $2M |
| Q3 2025 | Aug 7, 2025 | $0.85vs $0.86+1.2% | $730,000vs $1M-38.3% |
| Q2 2025 | May 8, 2025 | $0.81vs $0.75-8.0% | $695,000vs $1M-38.0% |
Based on last 12 quarters of dataView full earnings history →
CLDX Peer Comparison
Celldex Therapeutics, Inc. (CLDX) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 ALKS | 5.89B | 35.32 | 24.70 | -5.25% | 9.78% | 8.82% | 0.04 |
Compare CLDX vs Peers
Celldex Therapeutics, Inc. (CLDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLDX Income Statement
Celldex Therapeutics, Inc. (CLDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 12.74M | 9.54M | 3.57M | 7.42M | 4.65M | 2.36M | 6.88M | 7.02M | 1.5M |
| Revenue Growth % | 87.78% | -25.15% | -62.54% | 107.61% | -37.3% | -49.32% | 192.02% | 1.99% | -78.63% |
| Cost of Goods Sold | 96.17M | 66.45M | 42.67M | 42.53M | 53.31M | 82.26M | 118.01M | 163.55M | 0 |
| COGS % of Revenue | 754.7% | 696.68% | 1194.29% | 573.39% | 1146.23% | 3489.94% | 1714.53% | 2329.77% | - |
| Gross Profit | -83.43M▲ 0% | -56.91M▲ 31.8% | -39.1M▲ 31.3% | -35.12M▲ 10.2% | -48.66M▼ 38.6% | -79.9M▼ 64.2% | -111.13M▼ 39.1% | -156.53M▼ 40.9% | 1.5M▲ 101.0% |
| Gross Margin % | -654.7% | -596.68% | -1094.29% | -473.39% | -1046.23% | -3389.94% | -1614.53% | -2229.77% | 100% |
| Gross Profit Growth % | 12.4% | 31.78% | 31.3% | 10.19% | -38.57% | -64.2% | -39.08% | -40.86% | 100.96% |
| Operating Expenses | 38.1M | 99.53M | 15.93M | 28.24M | 22.58M | 35.33M | 43.41M | 38.55M | 288.9M |
| OpEx % of Revenue | 298.98% | 1043.46% | 445.9% | 380.67% | 485.55% | 1499.07% | 630.74% | 549.12% | 19260% |
| Selling, General & Admin | 25M | 19.27M | 15.43M | 14.46M | 20.49M | 27.2M | 30.91M | 38.55M | 43.8M |
| SG&A % of Revenue | 196.21% | 202.02% | 431.74% | 194.88% | 440.51% | 1153.8% | 449.14% | 549.12% | 2920% |
| Research & Development | 96.17M | 66.45M | 42.67M | 40.53M | 56.81M | 82.26M | 118.01M | 163.55M | 245.1M |
| R&D % of Revenue | 754.7% | 696.68% | 1194.29% | 546.43% | 1221.48% | 3489.94% | 1714.53% | 2329.77% | 16340% |
| Other Operating Expenses | -83.08M | 13.81M | -42.17M | -26.75M | -54.72M | -74.12M | -105.51M | -163.55M | 0 |
| Operating Income | -121.53M▲ 0% | -156.44M▼ 28.7% | -55.03M▲ 64.8% | -63.35M▼ 15.1% | -71.24M▼ 12.5% | -115.23M▼ 61.7% | -154.54M▼ 34.1% | -195.08M▼ 26.2% | -287.4M▼ 47.3% |
| Operating Margin % | -953.68% | -1640.13% | -1540.19% | -854.06% | -1531.78% | -4889.01% | -2245.27% | -2778.89% | -19160% |
| Operating Income Growth % | 8.57% | -28.73% | 64.82% | -15.12% | -12.45% | -61.75% | -34.11% | -26.23% | -47.33% |
| EBITDA | -116.22M | -152.63M | -50.17M | -59.42M | -68.17M | -112.34M | -151.53M | -191.9M | -284.02M |
| EBITDA Margin % | -912.01% | -1600.28% | -1404.23% | -801.09% | -1465.81% | -4766.14% | -2201.57% | -2733.63% | -18934.67% |
| EBITDA Growth % | 9.79% | -31.34% | 67.13% | -18.44% | -14.72% | -64.78% | -34.89% | -26.64% | -48% |
| D&A (Non-Cash Add-back) | 5.31M | 3.8M | 4.86M | 3.93M | 3.07M | 2.9M | 3.01M | 3.18M | 3.38M |
| EBIT | -109.33M | -76.4M | -54.52M | -49.57M | -69.15M | -107.1M | -142.04M | -195.08M | -287.4M |
| Net Interest Income | 4.21M | 4.49M | 4.15M | 2.41M | 505K | 2.91M | 13.11M | 37.22M | 28.61M |
| Interest Income | 4.21M | 4.49M | 4.15M | 2.41M | 505K | 2.91M | 13.11M | 37.22M | 28.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 4.21M | 4.49M | 4.15M | 2.41M | 505K | 2.91M | 13.11M | 37.22M | 28.6M |
| Pretax Income | -117.31M▲ 0% | -151.95M▼ 29.5% | -50.88M▲ 66.5% | -60.95M▼ 19.8% | -70.74M▼ 16.1% | -112.33M▼ 58.8% | -141.43M▼ 25.9% | -157.86M▼ 11.6% | -258.8M▼ 63.9% |
| Pretax Margin % | -920.61% | -1593.09% | -1423.96% | -821.61% | -1520.92% | -4765.59% | -2054.76% | -2248.76% | -17253.33% |
| Income Tax | -24.28M | -765K | 0 | -1.17M | -227K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 20.7% | 0.5% | 0% | 1.91% | 0.32% | 0% | 0% | 0% | 0% |
| Net Income | -93.03M▲ 0% | -151.18M▼ 62.5% | -50.88M▲ 66.3% | -59.78M▼ 17.5% | -70.51M▼ 18.0% | -112.33M▼ 59.3% | -141.43M▼ 25.9% | -157.86M▼ 11.6% | -258.8M▼ 63.9% |
| Net Margin % | -730.06% | -1585.07% | -1423.96% | -805.88% | -1516.04% | -4765.59% | -2054.76% | -2248.76% | -17253.33% |
| Net Income Growth % | 27.62% | -62.51% | 66.35% | -17.5% | -17.95% | -59.3% | -25.91% | -11.62% | -63.94% |
| Net Income (Continuing) | -93.03M | -151.18M | -50.88M | -59.78M | -70.51M | -112.33M | -141.43M | -157.86M | -258.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.86▲ 0% | -14.48▼ 33.3% | -3.51▲ 75.8% | -2.02▲ 42.5% | -1.64▲ 18.8% | -2.40▼ 46.3% | -2.92▼ 21.7% | -2.45▲ 16.1% | -3.90▼ 59.2% |
| EPS Growth % | 42.81% | -33.33% | 75.76% | 42.45% | 18.81% | -46.34% | -21.67% | 16.1% | -59.18% |
| EPS (Basic) | -10.86 | -14.48 | -3.51 | -2.02 | -1.64 | -2.40 | -2.92 | -2.45 | -3.90 |
| Diluted Shares Outstanding | 8.57M | 10.44M | 14.51M | 29.64M | 42.87M | 46.89M | 48.45M | 64.39M | 66.5M |
| Basic Shares Outstanding | 8.57M | 10.44M | 14.51M | 29.64M | 42.87M | 46.89M | 48.45M | 64.39M | 66.5M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CLDX Balance Sheet
Celldex Therapeutics, Inc. (CLDX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 144.76M | 99.08M | 66.7M | 197.84M | 410.84M | 317.69M | 431.69M | 747.16M | 534.66M |
| Cash & Short-Term Investments | 139.43M | 94.02M | 64.18M | 194.42M | 408.25M | 304.95M | 421.7M | 725.28M | 518.57M |
| Cash Only | 40.29M | 24.31M | 11.23M | 43.84M | 39.14M | 29.43M | 34.81M | 28.36M | 28.87M |
| Short-Term Investments | 99.14M | 69.71M | 52.95M | 150.59M | 369.11M | 275.52M | 386.88M | 696.92M | 489.7M |
| Accounts Receivable | 1.88M | 3.16M | 1.22M | 1.8M | 172K | 347K | 4.53M | 700K | 2.02M |
| Days Sales Outstanding | 53.85 | 121 | 124.12 | 88.67 | 13.5 | 53.74 | 240.12 | 36.4 | 490.32 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 5.47M | 21.18M | 14.08M |
| Total Non-Current Assets | 170.87M | 56.73M | 56.23M | 37.99M | 33.81M | 35.04M | 33.93M | 45.18M | 48.32M |
| Property, Plant & Equipment | 10.37M | 6.11M | 7.5M | 7.26M | 6.52M | 7.75M | 6.64M | 8.24M | 7.77M |
| Fixed Asset Turnover | 1.23x | 1.56x | 0.48x | 1.02x | 0.71x | 0.30x | 1.04x | 0.85x | 0.19x |
| Goodwill | 90.98M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 67.59M | 50.62M | 48.69M | 30.69M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.73M | 3.73M | 41K | 41K | 104K | 104K | 107K | 9.75M | 13.36M |
| Total Assets | 315.62M▲ 0% | 155.81M▼ 50.6% | 122.93M▼ 21.1% | 235.84M▲ 91.8% | 444.65M▲ 88.5% | 352.74M▼ 20.7% | 465.63M▲ 32.0% | 792.34M▲ 70.2% | 582.98M▼ 26.4% |
| Asset Turnover | 0.04x | 0.06x | 0.03x | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x |
| Asset Growth % | -17.67% | -50.63% | -21.1% | 91.84% | 88.54% | -20.67% | 32% | 70.17% | -26.42% |
| Total Current Liabilities | 27.74M | 12.6M | 11.64M | 14.21M | 16.53M | 18.61M | 31.13M | 39.5M | 50.99M |
| Accounts Payable | 1.72M | 1.07M | 1.17M | 1.05M | 1.23M | 3.34M | 3.49M | 3.27M | 1.18M |
| Days Payables Outstanding | 6.51 | 5.87 | 10.04 | 8.99 | 8.41 | 14.82 | 10.81 | 7.29 | - |
| Short-Term Debt | 6.57M | 4.53M | 1.94M | 0 | 0 | 0 | 0 | 0 | 1.55M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 2.01M | 3.37M | 1.55M | 990K | 3.99M | 942K | 48.26M |
| Current Ratio | 5.22x | 7.86x | 5.73x | 13.93x | 24.86x | 17.07x | 13.87x | 18.91x | 10.49x |
| Quick Ratio | 5.22x | 7.86x | 5.73x | 13.93x | 24.86x | 17.07x | 13.87x | 18.91x | 10.49x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 51.52M | 19.15M | 17.26M | 12.28M | 8.65M | 7.92M | 5.33M | 5.83M | 4.83M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 784K |
| Capital Lease Obligations | 0 | 0 | 1.71M | 2.15M | 1.3M | 2.59M | 928K | 2.36M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 51.52M | 19.15M | 15.55M | 10.12M | 7.35M | 5.33M | 4.4M | 3.47M | 4.04M |
| Total Liabilities | 79.25M | 31.75M | 28.91M | 26.48M | 25.18M | 26.53M | 36.46M | 45.34M | 55.82M |
| Total Debt | 6.57M | 4.53M | 3.66M | 3.48M | 3.04M | 4.03M | 2.54M | 3.81M | 2.34M |
| Net Debt | -33.72M | -19.78M | -7.58M | -40.35M | -36.1M | -25.4M | -32.27M | -24.54M | -26.54M |
| Debt / Equity | 0.03x | 0.04x | 0.04x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 236.37M▲ 0% | 124.06M▼ 47.5% | 94.03M▼ 24.2% | 209.36M▲ 122.7% | 419.48M▲ 100.4% | 326.2M▼ 22.2% | 429.17M▲ 31.6% | 747M▲ 74.1% | 527.16M▼ 29.4% |
| Equity Growth % | -10.95% | -47.51% | -24.21% | 122.66% | 100.36% | -22.24% | 31.57% | 74.06% | -29.43% |
| Book Value per Share | 27.58 | 11.88 | 6.48 | 7.06 | 9.78 | 6.96 | 8.86 | 11.60 | 7.93 |
| Total Shareholders' Equity | 236.37M | 124.06M | 94.03M | 209.36M | 419.48M | 326.2M | 429.17M | 747M | 527.16M |
| Common Stock | 139K | 12K | 17K | 40K | 47K | 47K | 56K | 66K | 67K |
| Retained Earnings | -812.52M | -962.44M | -1.01B | -1.07B | -1.14B | -1.26B | -1.4B | -1.56B | -1.81B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.56M | 2.58M | 2.62M | 2.59M | 1.89M | 1.26M | 3.31M | 3.31M | 3.63M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLDX Cash Flow Statement
Celldex Therapeutics, Inc. (CLDX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -99.93M | -75.23M | -46.41M | -40.4M | -60.91M | -103.73M | -107.29M | -157.78M | -210.94M |
| Operating CF Margin % | -784.2% | -788.79% | -1299.05% | -544.68% | -1309.59% | -4401.02% | -1558.78% | -2247.55% | -14063% |
| Operating CF Growth % | 11.59% | 24.71% | 38.31% | 12.95% | -50.75% | -70.31% | -3.43% | -47.06% | -33.7% |
| Net Income | -93.03M | -151.18M | -50.88M | -59.78M | -70.51M | -112.33M | -141.43M | -157.86M | -258.76M |
| Depreciation & Amortization | 5.31M | 3.8M | 4.86M | 3.93M | 3.07M | 1.4M | 3.01M | 3.18M | -2.48M |
| Stock-Based Compensation | 12.31M | 8.08M | 4.55M | 3.92M | 8.95M | 0 | 23.89M | 34.24M | 36.22M |
| Deferred Taxes | -24.28M | -765K | 671K | -1.17M | -227K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 11.96M | 80.2M | -1.29M | 13M | -1.14M | 11.09M | -6.22M | -15.73M | 14.07M |
| Working Capital Changes | -12.21M | -15.37M | -4.32M | -299K | -1.05M | -3.9M | 13.46M | -21.6M | 0 |
| Change in Receivables | -96K | -777K | -777K | -787K | 1.57M | -175K | -2.28M | 1.93M | -1.31M |
| Change in Inventory | -3.57M | 1.78M | 13.89M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -8.74M | -13.11M | -13.11M | 1.64M | 3.65M | 3.12M | 9.38M | 11.63M | 11.03M |
| Cash from Investing | 46.47M | 29.82M | 17.08M | -98.22M | -216.16M | 89.94M | -105.78M | -290.13M | 209.07M |
| Capital Expenditures | -1.79M | -813K | -731K | -1.55M | -1.25M | -1.83M | -1.82M | -1.92M | 0 |
| CapEx % of Revenue | 14.03% | 8.52% | 20.46% | 20.92% | 26.85% | 77.56% | 26.41% | 27.34% | - |
| Acquisitions | 1.79M | 342K | 20K | 55K | 27K | 69K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.79M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.71M |
| Cash from Financing | 51.29M | 29.44M | 16.26M | 171.23M | 272.37M | 4.08M | 218.46M | 441.45M | 2.39M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 265K | 419K | 9K | 434K | 2.48M | 0 | 2.24M | 9.15M | 2.39M |
| Net Change in Cash | -2.17M▲ 0% | -15.98M▼ 635.3% | -13.08M▲ 18.1% | 32.6M▲ 349.3% | -4.69M▼ 114.4% | -9.71M▼ 107.0% | 5.38M▲ 155.4% | -6.46M▼ 219.9% | 515K▲ 108.0% |
| Free Cash Flow | -101.72M▲ 0% | -76.05M▲ 25.2% | -47.15M▲ 38.0% | -41.96M▲ 11.0% | -62.16M▼ 48.2% | -105.56M▼ 69.8% | -109.11M▼ 3.4% | -159.7M▼ 46.4% | -210.94M▼ 32.1% |
| FCF Margin % | -798.23% | -797.32% | -1319.51% | -565.6% | -1336.44% | -4478.57% | -1585.2% | -2274.89% | -14063% |
| FCF Growth % | 12.15% | 25.24% | 38% | 11.01% | -48.15% | -69.83% | -3.36% | -46.36% | -32.09% |
| FCF per Share | -11.87 | -7.28 | -3.25 | -1.42 | -1.45 | -2.25 | -2.25 | -2.48 | -3.17 |
| FCF Conversion (FCF/Net Income) | 1.07x | 0.50x | 0.91x | 0.68x | 0.86x | 0.92x | 0.76x | 1.00x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLDX Key Ratios
Celldex Therapeutics, Inc. (CLDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -46.27% | -37.08% | -83.89% | -46.66% | -39.41% | -22.43% | -30.13% | -37.45% | -26.84% | -40.62% |
| Return on Invested Capital (ROIC) | -44.76% | -42.83% | -76.45% | -43.28% | -37.2% | -19.35% | -25.26% | -33.23% | -26.14% | -35.25% |
| Gross Margin | -1403.48% | -654.7% | -596.68% | -1094.29% | -473.39% | -1046.23% | -3389.94% | -1614.53% | -2229.77% | 100% |
| Net Margin | -1894.05% | -730.06% | -1585.07% | -1423.96% | -805.88% | -1516.04% | -4765.59% | -2054.76% | -2248.76% | -17253.33% |
| Debt / Equity | - | 0.03x | 0.04x | 0.04x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x |
| FCF Conversion | 0.88x | 1.07x | 0.50x | 0.91x | 0.68x | 0.86x | 0.92x | 0.76x | 1.00x | 0.82x |
| Revenue Growth | 23.83% | 87.78% | -25.15% | -62.54% | 107.61% | -37.3% | -49.32% | 192.02% | 1.99% | -78.63% |
CLDX SEC Filings & Documents
Celldex Therapeutics, Inc. (CLDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CLDX Frequently Asked Questions
Celldex Therapeutics, Inc. (CLDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Celldex Therapeutics, Inc. (CLDX) reported $1.5M in revenue for fiscal year 2025. This represents a 36% increase from $1.1M in 1996.
Celldex Therapeutics, Inc. (CLDX) saw revenue decline by 78.6% over the past year.
Celldex Therapeutics, Inc. (CLDX) reported a net loss of $258.8M for fiscal year 2025.
Dividend & Returns
Celldex Therapeutics, Inc. (CLDX) has a return on equity (ROE) of -40.6%. Negative ROE indicates the company is unprofitable.
Celldex Therapeutics, Inc. (CLDX) had negative free cash flow of $213.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More CLDX
Celldex Therapeutics, Inc. (CLDX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates